{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:06:32Z","timestamp":1774940792523,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Adeno-Associated virus (AAV) vectors have become an invaluable tool in research and the clinic. Likewise, AAV is used in various animal models for investigating a host of diseases. However, AAV shedding, or the release of AAV particles from the body, remains an understudied field which could be detrimental to researchers and be a potential contributor to pre-clinical variability. To our knowledge, no studies have been performed to evaluate any relationship between AAV shed particles and the effects these particles may have on cage mates. As such, we evaluated the level of AAV viral genomes in the fecal matter of C57BL6\/J mice following the intravenous administration of AAV8. Here we show that AAV genomes are shed from female C57BL\/6J mice for a minimum of 2 months following intravenously injected AAV8 vector. We also sought to determine if these shed AAV particles could affect non-vectored cage mates in experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). We found an association between caging vectored animals with non-vectored animals and a reduction in disease severity in the non-vectored animals. We also found an association between disease severity and the ratio of vectored:non-vectored animals in the cage. Our findings should act as a word of caution to researchers performing AAV studies and should be considered to prevent confounding variables and bias in results.<\/jats:p>","DOI":"10.3389\/fmed.2026.1810215","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:34:30Z","timestamp":1774935270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fecal AAV8 shedding and co-housing reduces EAE disease severity: implications for preclinical study design"],"prefix":"10.3389","volume":"13","author":[{"given":"Cristina D.","family":"Gaddie","sequence":"first","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Keeler","sequence":"additional","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0295725","DOI":"10.1128\/mbio.02957-25","article-title":"mGem: AAV, from almost a virus to an awesome vector-or is it?","volume":"17","author":"Srivastava","year":"2026","journal-title":"mBio."},{"key":"B2","volume-title":"Sarepta Reports 2nd Death After DMD Gene Therapy Elevidys, Stops Dosing in Half of Patients.","author":"Liu","year":"2025"},{"key":"B3","volume-title":"Amicus Axes Gene Therapy Program for Type of Batten Disease, Advances Another.","author":"Armstrong","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1089\/humc.2019.29050.bfs","article-title":"Gene therapy briefs.","volume":"30","author":"Philippidis","year":"2019","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1089\/hum.2020.29139.bfs","article-title":"\u201cProfoundly saddened\u201d; Lysogene discloses child\u2019s death in phase II\/III trial.","volume":"31","author":"Philippidis","year":"2020","journal-title":"Hum Gene Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/hum.2022.29211.bfs","article-title":"Food and drug administration lifts clinical hold on pfizer duchenne muscular dystrophy gene therapy linked to patient death.","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy zolgensma.","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/hum.2024.38567.bfs","article-title":"Pfizer weighs next steps after DMD therapy linked to boy\u2019s death fails phase III Trial.","volume":"35","author":"Philippidis","year":"2024","journal-title":"Hum Gene Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","article-title":"Fourth boy dies in clinical trial of Astellas\u2019 AT132.","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41434-025-00535-8","article-title":"Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy.","volume":"32","author":"Pongsakornkullachart","year":"2025","journal-title":"Gene Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMc2312288","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy.","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med."},{"key":"B13","volume-title":"Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome.","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/10430342251366176","article-title":"FDA investigating Sarepta\u2019s Elevidys\u00ae after second patient dies.","volume":"36","author":"Philippidis","year":"2025","journal-title":"Hum Gene Ther."},{"key":"B15","volume-title":"Analyst Demand Transparency After Sarepta\u2019s Roundabout Disclosure of 3rd Patient Death.","author":"Kansteiner","year":"2025"},{"key":"B16","volume-title":"Rocket Crashes as Gene Therapy Patient Dies, FDA Imposes Hold.","author":"Taylor","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41434-024-00447-z","article-title":"A shedding analysis after AAV8 CNS injection revealed fragmented viral DNA without evidence of functional AAV particles in mice.","volume":"31","author":"Krause","year":"2024","journal-title":"Gene Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","article-title":"Non-clinical safety and efficacy of an AAV2\/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI.","volume":"6","author":"Ferla","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","article-title":"Gene therapy-induced antigen-specific tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis.","volume":"26","author":"Keeler","year":"2018","journal-title":"Mol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.omtm.2022.12.011","article-title":"Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background.","volume":"28","author":"Keeler","year":"2022","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.addr.2012.10.013","article-title":"Mechanism of oral tolerance induction to therapeutic proteins.","volume":"65","author":"Wang","year":"2013","journal-title":"Adv Drug Deliv Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1038\/s41467-024-53814-0","article-title":"Dietary nucleic acids promote oral tolerance through innate sensing pathways in mice.","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41586-020-2971-8","article-title":"The gut microbiota is associated with immune cell dynamics in humans.","volume":"588","author":"Schluter","year":"2020","journal-title":"Nature."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases.","volume":"23","author":"Miyauchi","year":"2023","journal-title":"Nat Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.1073\/pnas.1711233114","article-title":"Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.","volume":"114","author":"Berer","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2015.05.014","article-title":"Immune-microbiota interactions in health and disease.","volume":"159","author":"Palm","year":"2015","journal-title":"Clin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2018.05.001","article-title":"Helper-free production of laboratory grade AAV and purification by iodixanol density gradient centrifugation.","volume":"10","author":"Crosson","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/hgtb.2013.131","article-title":"Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR.","volume":"25","author":"Lock","year":"2014","journal-title":"Hum Gene Ther Methods."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:34:32Z","timestamp":1774935272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1810215"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1810215","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1810215"}}